Peritoneal Surface Malignancies

E337: The Impact of Surgical Volume and the Institutional Learning Curve on Cost in Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC)

E338: An Explainable Machine Learning Framework for Predicting Textbook Outcome After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy

E339: Predicting 90-Day Readmissions Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Nested Case-Control Study

E340: The use of ROTEM in detection of coagulopathy and altered hemostasis in patients undergoing CRS/HIPEC

E341: External Validation of Nomograms Predicting 30-Day Mortality in Malignant Bowel Obstruction Patients

E342: Clinical implications of tumor mutational burden in patients with colorectal peritoneal metastasis

E343: Outcomes from Selective Hyperthermic Intraperitoneal Chemotherapy for Colorectal Cancer Patients in the Post-PRODIGE 7 Era

E344: Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Management of Appendix Cancer with Peritoneal and Parenchymal Metastases: the National Cancer Database Analysis

E345: Novel scoring system to assess the response to PIPAC therapy in patients with peritoneal cancer

E346: Feasibility of the pegulicianine fluorescence guided surgery for detection of peritoneal surface malignancies

E347: Use of Novel Epigenetic Therapy Agent Romidepsin in Cytoreductive Surgery for Peritoneal Colorectal Cancer

E348: Neoadjuvant Chemotherapy Prior to Cytoreductive Surgery and Heated Intraperitoneal Chemoperfusion for Patients with Metachronous Colorectal Peritoneal Metastases: Experience at a High Volume Center

E350: Increasing Incidence of Appendiceal Cancers in the United States

E351: Minimally Invasive Approach to Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Improves Perioperative Outcomes

E352: Implementation of a multidisciplinary Enhanced Recovery After Surgery program for Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

E353: Single cell transcriptomic analysis reveals differences between primary appendiceal tumors.

E354: Long-term outcomes following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin.

E355: Association of Negative Pressure Wound Therapy (NPWT) and Surgical Site Infections in Patients Undergoing Cytoreductive Surgery

E356: Systemic Inflammatory Markers: Predictors for Early Morbidity and Survival in Appendiceal Cancer Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

E357: Peritoneal Cancer Index Correlates with Radiographic Assessment in Colorectal Carcinomatosis

E359: Is cytoreductive surgery without HIPEC the optimal strategy for managing patients with massive pseudomyxoma peritonei ?

E360: Perihepatic tumor burden in pseudomyxoma peritonei predicts complexity of cytoreductive surgery and risk of recurrence but not resectability or survival

E361: Peritoneal Carcinomatosis in the Elderly: Too Old for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC)?

E362: Effect of Travel Distance on Outcomes of Patients with Malignant Peritoneal Mesothelioma Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

E363: Feasability , compliance and clinical outcomes of ERAS implementation in cytoreductive surgeries with or without HIPEC

E364: Higher Number of Anesthesia Handoffs Do Not Increase Cost of CRS-HIPEC

E365: Gastrectomy for Patients with Gastric Cancer Peritoneal Metastases: Safety and Outcomes from an Initial Experience

E366: Predictive Value of CRP for Infectious Complications after Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy: A single-center Prospective Study

E367: Early Experience and Quality Outcomes from a Community Peritoneal Surface Malignancies Program

E368: Low Grade Appendiceal Mucinous Neoplasms (LAMN): Recurrence Risk and Disease Surveillance

E369: Patterns and Outcomes of Post-Operative Systemic Therapy for Colorectal Peritoneal Metastasis Patients Who Undergo Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy with Complete Cytoreduction

E370: Single cell transcriptomic analysis of malignant peritoneal mesothelioma: finding the tumor cells?

E371: Navigating Neutropenia: Risk Factors and Outcomes Following Hyperthermic Intraperitoneal Chemotherapy with Mitomycin C

E372: Pathway to Publication: Results from the 2018-2021 Society of Surgical Oncology Conference Abstracts for Peritoneal Surface Malignancies

P46: TWIST1 as a potential master transcription factor regulating colorectal cancer metastasis

P47: Understanding the Navigation Needs of Peritoneal Surface Malignancy Patients: Insights from Patients, Caregivers, and Providers

P48: Preliminary Analysis of a Phase II Randomized Comparison of Flat vs Weight-based Mitomycin C Intraperitoneal Chemotherapy

P49: The Immune and Transcriptomic Landscape of Appendix Cancer Peritoneal Disease

P50: Beyond Standard Measures: A Comprehensive Evaluation of Quality of Life in Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Survivors

P52: Updated Report of a Randomized Trial for Appendiceal Neoplasm Ten Years After Cytoreduction and HIPEC With Mitomycin vs. Oxaliplatin

P53: Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) for Peritoneal Metastasis from Gastrointestinal Malignancy: Evaluation of Treatment Response in a Single Tertiary Center